Form 4: Takeda Converts Ovid Preferred Stock, Adjusts Common Holdings

Takeda Pharmaceutical Co Ltd converted 1,250 shares of Ovid Therapeutics Inc. Series A Preferred Stock into 1.25 million common shares and reported a net beneficial ownership of 7 million common shares after a disposition.

Summary

• Takeda Pharmaceuticals U.S.A., Inc. (TPUSA), a subsidiary of Takeda Pharmaceutical Company Limited, converted all 1,250 shares of Series A Convertible Preferred Stock of Ovid Therapeutics Inc. into common stock.
• Each share of Series A Preferred Stock was convertible into 1,000 shares of Ovid's common stock.
• This conversion resulted in the acquisition of 1,250,000 shares of Ovid common stock by TPUSA on December 8, 2025.
• Additionally, 1,781,996 shares of Ovid common stock were disposed of.
• Following these transactions, Takeda Pharmaceutical Co Ltd, through its subsidiary TPUSA, beneficially owns 7,000,000 shares of Ovid common stock indirectly.

Sentiment

Score: 5

Explanation: The filing is a factual report of an insider transaction, indicating a strategic adjustment rather than a clear positive or negative operational event. The net disposition of common shares slightly offsets the positive of simplifying the capital structure.

Positives

• The conversion of preferred stock into common stock simplifies the capital structure for Ovid Therapeutics Inc.
• Takeda's continued significant indirect beneficial ownership of 7,000,000 common shares indicates ongoing strategic interest in Ovid.

Negatives

• A net disposition of 531,996 common shares (1,250,000 acquired 1,781,996 disposed) by a 10% owner could be interpreted as a slight reduction in direct equity exposure.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4.

Industry Context

This transaction reflects a strategic adjustment in a significant investor's holdings within the biopharmaceutical sector. Takeda, a global pharmaceutical leader, maintains a substantial stake in Ovid Therapeutics, a company focused on neurological disorders.

Related Party Transactions

• The transaction involves Takeda Pharmaceutical Co Ltd, a 10% owner and director of Ovid Therapeutics Inc. through its subsidiary, making it a related party transaction.

Stakeholder Impact

• Shareholders: Existing Ovid shareholders will see a change in the ownership structure, with Takeda converting preferred shares to common and adjusting its overall common stock holdings. This could impact perceptions of institutional confidence.
• Company (Ovid): The conversion simplifies Ovid's capital structure by reducing outstanding preferred stock.

Key Dates

Keywords

Ovid Therapeutics, Takeda Pharmaceutical, Form 4, SEC filing, beneficial ownership, common stock, preferred stock, stock conversion, insider transaction, pharmaceutical, biotechnology